Myeloma XII opens for recruitment

The latest national myeloma trial, Myeloma XII, has recently opened for patient recruitment. The aim of this Phase III trial is to determine whether ixazomib (Ninlaro┬«) has a significant impact on the depth and duration of response when used as an augmented conditioning treatment in salvage autologous stem cell transplantation (ASCT) and then as post-transplant…

Details